Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 28:11:356.
doi: 10.1186/1471-2334-11-356.

The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?

Magnus Gisslén  1 , Richard W Price, Staffan Nilsson
Affiliations

The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?

Magnus Gisslén et al. BMC Infect Dis. .

Abstract

Background: A substantial prevalence of mild neurocognitive disorders has been reported in HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a new disorder that has been termed asymptomatic neurocognitive impairment (ANI).

Discussion: ANI is identified by performance on formal neuropsychological testing that is at least 1 SD below the mean of normative scores in at least two cognitive domains out of at least five examined in patients without associated symptoms or evident functional impairment in daily living. While two tests are recommended to assess each domain, only one is required to fulfill this diagnostic criterion. Unfortunately, this definition necessitates that about 20% of the cognitively normal HIV-infected population is classified as suffering ANI. This liberal definition raises important ethical concerns and has as well diagnostic and therapeutic implications. Since neither its biological substrate, prognostic significance nor therapeutic implications are clearly established, we recommend that this diagnosis be modified or applied cautiously.

Summary: The diagnoses of less severe forms of neurocognitive disorders in HIV relies on the outcomes of neuropsychological testing, and a high proportion of HIV-infected patients with effective cART may be classified as neurocognitively abnormal using the current criteria. The definition of ANI is not stringent, and results in approximately 20% of the population being classified as abnormal. To us this seems an unacceptable false-positive rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Probability of a normal control to be categorized as abnormal according to the criteria of asymptomatic neurocognitive impairment (ANI) and minor neurocognitive disorder (MND) if five cognitive domains are tested. Defined as impairment in functioning, involving at least two ability domains, documented by performance of at least 1.0 SD below the mean for norms in one test per domain (blue solid line), in two tests per domain (blue dotted line) or of at least 1.5 SD below mean for norms in one test per domain (red line). The probability is plotted as a function of the degree of correlation between test results of different cognitive domains with using 0.8 as correlation between tests in the same domain.
See this image and copyright information in PMC

References

    1. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55(3):320–328. doi: 10.1002/ana.10827. - DOI - PubMed
    1. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2):213–221. doi: 10.1002/ana.21225. - DOI - PubMed
    1. Lescure FX, Omland LH, Engsig FN, Roed C, Gerstoft J, Pialoux G, Kronborg G, Larsen CS, Obel N. Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis. 2011;52(2):235–243. doi: 10.1093/cid/ciq041. - DOI - PubMed
    1. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH. et al.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–2096. doi: 10.1212/WNL.0b013e318200d727. - DOI - PMC - PubMed
    1. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915–1921. doi: 10.1097/QAD.0b013e32828e4e27. - DOI - PubMed

MeSH terms